Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022.

Autor: Rothermundt C; Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. Electronic address: christian.rothermundt@kssg.ch., Andreou D; Department of Orthopedics and Trauma, Medical University of Graz, Graz, Austria., Blay JY; Department of Medicine, Léon Bérard Center, Lyon, France., Brodowicz T; Department of Medical Oncology, General Hospital - Medical University of Vienna, Vienna, Austria., Desar IME; Department of Medical Oncology, Radboud University Medical Center Nijmegen, the Netherlands., Dileo P; London Sarcoma Service, Department of Oncology, University College Hospital London, United Kingdom., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Haas R; Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam and the Leiden University Medical Center, Leiden, the Netherlands., Jakob J; Sarcoma Unit, Department of Surgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany., Jones RL; Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom., Judson I; The Institute of Cancer Research, London, United Kingdom., Kunz WG; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Liegl-Atzwanger B; Diagnostic and Research Institute of Pathology, Medical University Graz, Graz, Austria., Lindner LH; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Messiou C; Department of Radiology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom., Miah AB; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom., Reichardt P; Department of Oncology and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, Germany., Szkandera J; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., van der Graaf WTA; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Houdt WJ; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wardelmann E; Gerhard-Domagk-Institute of Pathology, University Hospital Muenster, Muenster, Germany., Hofer S; Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Feb; Vol. 180, pp. 158-179. Date of Electronic Publication: 2022 Nov 16.
DOI: 10.1016/j.ejca.2022.11.008
Abstrakt: Background: Owing to the rarity and heterogeneity in biology and presentation, there are multiple areas in the diagnosis, treatment and follow-up of soft tissue sarcoma (STS), with no, low-level or conflicting evidence.
Methods: During the first Consensus Conference on the State of Science in Sarcoma (CSSS), we used a modified Delphi process to identify areas of controversy in the field of sarcoma, to name topics with limited evidence-based data in which a scientific and knowledge gap may remain and a consensus statement will help to guide patient management. We determined scientific questions which need to be addressed in the future in order to generate evidence and to inform physicians and caregivers in daily clinical practice in order to improve the outcomes of patients with sarcoma. We conducted a vote on STS key questions and controversies prior to the CSSS meeting, which took place in May 2022.
Results: Sixty-two European sarcoma experts participated in the survey. Sixteen strong consensus (≥95%) items were identified by the experts, as well as 30 items with a ≥75% consensus on diagnostic and therapeutic questions. Ultimately, many controversy topics remained without consensus.
Conclusions: In this manuscript, we summarise the voting results and the discussion during the CSSS meeting. Future scientific questions, priorities for clinical trials, registries, quality assurance, and action by stakeholders are proposed. Platforms and partnerships can support innovative approaches to improve management and clinical research in STS.
Competing Interests: Conflict of interest statement The authors declare following conflicts of interest: CR: Consulting or Advisory Role (Payment to Institution): Bayer (Schweiz) AG, Bristol-Myers Squibb, Ipsen, MSD Oncology, Pfizer; Consulting or Advisory Role (Payment to me): Merck (Schweiz) AG; Travel Expenses (Payment to me): PharmaMar; Research Funding (Payment to Institution): Astellas Pharma AG. DA: has received institutional research support from Implantcast GmbH and invited speaker fees from PharmaMar.WGK: served as advisor to Bristol Myers Squibb, unrelated. JYB: grants or research support from AstraZeneca, Bayer, Bristol Myers Squibb, Deciphera, Glaxo SmithKline, Merck Sharp & Dohme, Novartis, PharmaMar, and Roche; has an advisory or board member role in Innate Pharma; and receives honorarium from Bayer, Deciphera, Novartis, and Roche. ID: no COI. PD: Honoraria for consultancy or advisory role: Ayala Pharmaceuticals, Deciphera. RH: no COI. JJ: has received travel expenses or honoraria for participation in advisory boards or invited speaker fees from PharmaMar, Pfizer and Belpharma. LHL: Honoraria and compensation for advisory boards: Boehringer Ingelheim, Novartis, Lilly, Eisai, EL Medconsult, Roche; Travel and research grants: Dr. Sennewald Medizintechnik; Travel grants: PharmaMar; Stockownerships: Thermosome (co-founder) CM: no COI. ABM: Trustee Sarcoma UK, no other conflict of interest. TB: reports personal fees from PharmaMar and Deciphera (lecture fee, advisory board) ABM: Trustee Sarcoma UK, no other conflict of interest. RLJ: Receipt of grants/research support: MSD, GSK. Receipt of consultation fees: Adaptimmune, Astex, Athenex, Bayer, Boehringer Ingelheim, Blueprint, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Immunicum, Karma Oncology, Lilly, Merck, Mundipharma, Pharmamar, Springworks. SynOx, Tracon, Up to Date. IJ: No conflicts of interest. PR: has received honoraria for participation in advisory boards for Bayer, Novartis, Roche, Deciphera, Mundibiopharma, PharmaMar, Blueprint Medicines, GSK, Boehringer Ingelheim and invited speaker fees from Clinigen, Deciphera, PharmaMar, Boehringer Ingelheim. JS: Participation in advisory boards or invited speaker fees: PharmaMar, Bayer, Roche, Lilly, Amgen; Travel expenses: PharmaMar, Roche, Lilly, Amgen, Bristol Myers Squibb; Research funding: PharmaMar, Roche, Eisai. WvdG: research grant funding from Eli Lilly, advisory board participation Springworks, Bayer, PTC Therapeutics – all to the institute. WJvH: received institutional honoraria for participation in advisory board for Belpharma, invited speaker fees from Amgen andreports expert testimony for Sanofi and MSD and personal travel grant from Novartis and institutional research grant from BMS. EW: has received honoraria for participation in advisory boards or invited speaker fees from Bayer, Roche, Deciphera, Boehringer Ingelheim, Bristol Myers Squibb, PharmaMar. SH: no COI.
(Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: